Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.62 |
| ▸ | ADA | P00813 | 1/20 | 0.55 |
| ▸ | NT5E | P21589 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | AHCY | P23526 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL465590 | 1.00 | ADORA2A (0.62) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL15038015 | 1.00 | ADORA2A (0.62) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL20991001 | 1.00 | ADORA2A (0.62) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL12849772 | 1.00 | ADORA2A (0.62) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL13929038 | 1.00 | ADORA2A (0.62) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL18061789 | 1.00 | ADORA2A (0.62) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL15908440 | 0.91 | ADORA2A (0.52) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL13066843 | 0.90 | ADORA2A (0.53) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL12202863 | 0.90 | ADORA2A (0.53) | ADORA2AADANT5ELMNAHIF1A | |
| SCHEMBL1552038 | 0.90 | ADORA2A (0.53) | ADORA2AADANT5ELMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023069495-A1 | OLIGONUCLEOTIDES WITH 2'-DEOXY-2'-F-2'-C-METHYL NUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, LTD. (BB) | 2019-10-17 | — | — | US | disclosed |
| EP-3497111-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen BioPharma, Inc. (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2019-06-06 | — | — | US | disclosed |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | GILEAD PHARMASSET LLC (US) | 2019-05-14 | — | — | US | disclosed |
| WO-2018031818-A2 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2018-02-15 | — | — | WO | disclosed |
| US-20140212382-A1 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | EMORY UNIVERSITY (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140205566-A1 | CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-07-24 | — | — | US | disclosed |
| WO-2014082935-A1 | CYCLIC NUCLEOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| EP-2345658-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| EP-2345661-A1 | Modified fluorinated nucleoside analogues | Pharmasset, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7429572-B2 | Modified fluorinated nucleoside analogues | PHARMASSET, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| EP-1633766-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | Pharmasset, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | GILEAD SCIENCES, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2005003147-A2 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | PHARMASSET, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070861-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
| US-20140212382-A1 | PURINE MONOPHOSPHATE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS | PNP, MTAP, NT5C3B | ADORA2A 83/4885ADA 35/4885NT5E 84/4885 |
| US-10287311-B2 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
| US-20190315792-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
| US-20190169221-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ADORA2A 71/4885ADA 18/4885NT5E 13/4885 |
| US-20050009737-A1 | Modified fluorinated nucleoside analogues | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
| US-20110038833-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
| US-20140205566-A1 | CYCLIC NUCLEUOSIDE DERIVATIVES AND USES THEREOF | NSUN2, NSUN3, DDX21 | ADORA2A 1924/4885ADA 374/4885NT5E 608/4885 |
| US-20090004135-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
| US-20080253995-A1 | MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES | NSUN2, NT5C3B, METTL3 | ADORA2A 61/4885ADA 80/4885NT5E 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.